RxDoctor Payments Data

Luke Mosel, DO

Anesthesiology · Shreveport, LANPI 1356846430

Payments from drug & device makers

What this record shows

This record is dominated by grants: $10,000 of the $14,221 with a category attached, or 70.3%. Medtronic accounts for 86.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $11,535 and has fallen 95.5% since, to $520 in 2025. Among anesthesiology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,221in general payments, 2019–2025

Across 91 payments — averaging $156.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • Boston Scientific$1K
  • Forte Bio-pharma LLC$162
  • Collegium Pharmaceutical, Inc.$123
  • Curonix LLC$98
  • Relievant Medsystems, Inc.$87
  • plus $294 from 10 others

What the payments were for

  • Grants$10,00070%
  • Travel & lodging$1,65612%
  • Food & beverage$2,56518%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,221 in reported general payments places this provider in the 95th percentile of 497 anesthesiology providers in Louisiana.

See all anesthesiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$604,708
Medicare patients
914
Services billed
8,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl179$158,828
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen811$76,670
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,221$67,255
Buprenorphine214$61,931
BelsomraSuvorexant109$46,773
Xtampza ErOxycodone Myristate47$26,620
NucyntaTapentadol Hcl15$16,562
LinzessLinaclotide27$14,386
OxycontinOxycodone Hcl26$14,383
MovantikNaloxegol Oxalate34$13,492
QuliptaAtogepant12$13,383
Oxycodone Hcl591$10,951
Gabapentin485$8,266
Morphine Sulfate ErMorphine Sulfate272$6,735
Lidocaine77$6,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$123$202,010241 claims
MerckBelsomra$18$46,773109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 497 anesthesiology providers in Louisiana.

Other anesthesiology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →